Next Article in Journal
A Humanized Yeast Model for Studying TRAPP Complex Mutations; Proof-of-Concept Using Variants from an Individual with a TRAPPC1-Associated Neurodevelopmental Syndrome
Previous Article in Journal
Modulation of Spontaneous Action Potential Rate by Inositol Trisphosphate in Myocytes from the Rabbit Atrioventricular Node
Previous Article in Special Issue
Latest in Cellular Pathology Research
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cells
Volume 13
Issue 17
10.3390/cells13171456
cells-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Correction to Cells 2022, 11(2), 305.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Asadian et al. Rhenium Perrhenate (188ReO4) Induced Apoptosis and Reduced Cancerous Phenotype in Liver Cancer Cells. Cells 2022, 11, 305

by
Samieh Asadian
1,2,
Abbas Piryaei
3,4,
Nematollah Gheibi
1,*,
Bagher Aziz Kalantari
5,
Mohamad Reza Davarpanah
6,
Mehdi Azad
1,
Valentina Kapustina
7,
Mehdi Alikhani
2,
Sahar Moghbeli Nejad
1,
Hani Keshavarz Alikhani
2,
Morteza Mohamadi
8,
Anastasia Shpichka
9,10,11,
Peter Timashev
9,10,11,*,
Moustapha Hassan
12,13 and
Massoud Vosough
2,12,13,*
1
Cellular and Molecular Research Center, Research Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin 34199153, Iran
2
Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran 16635148, Iran
3
Department of Biology and Anatomical Sciences, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran 16123798, Iran
4
Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran 16123798, Iran
5
Department of Organic Chemistry, Karaj Branch, Islamic Azad University, Karaj 16255879, Iran
6
Faculty of Nuclear Engineering, Shahid Beheshti University, Tehran 15689456, Iran
7
Department of Internal Medicine N1, Sechenov University, 119991 Moscow, Russia
8
Department of Physical Chemistry, Faculty of Science, University of Tehran, Tehran 17456987, Iran
9
World-Class Research Center “Digital Biodesign and Personalized Healthcare”, Sechenov University, 119991 Moscow, Russia
10
Institute for Regenerative Medicine, Sechenov University, 119991 Moscow, Russia
11
Chemistry Department, Lomonosov Moscow State University, 119991 Moscow, Russia
12
Experimental Cancer Medicine, Institution for Laboratory Medicine, Karolinska Institute, 141-83 Stockholm, Sweden
13
Clinical Research Center, Karolinska University Hospital Huddinge, 141-83 Stockholm, Sweden
 
add Show full affiliation list
 
remove Hide full affiliation list
*
Authors to whom correspondence should be addressed.
Cells 2024, 13(17), 1456; https://doi.org/10.3390/cells13171456
Submission received: 14 August 2024 / Accepted: 19 August 2024 / Published: 30 August 2024
(This article belongs to the Special Issue 10th Anniversary of Cells—Advances in Cellular Pathology)
Browse Figure
Versions Notes
In the original publication [1], there was a mistake in Figure 1A as published. The two upper-right images were repeated unintentionally in the neighboring boxes. In addition, the control figures on the left side overlapped. Figure 1A has been corrected and appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Asadian, S.; Piryaei, A.; Gheibi, N.; Aziz Kalantari, B.; Reza Davarpanah, M.; Azad, M.; Kapustina, V.; Alikhani, M.; Moghbeli Nejad, S.; Keshavarz Alikhani, H.; et al. Rhenium Perrhenate (188ReO4) Induced Apoptosis and Reduced Cancerous Phenotype in Liver Cancer Cells. Cells 2022, 11, 305. [Google Scholar] [CrossRef] [PubMed]
Cells 13 01456 g001
Figure 1. 188ReO4 IC50 dose finding on Huh7 and HepG2 cell lines. Huh7 cells viability was measured using LIVE/DEAD® Viability/Cytotoxicity Kit and the mean viability of untreated cells (control group), and the treated groups were compared on various doses of 18, 37, and 55 MBq of 188ReO4 at 18, 24, and 48 h post-exposure for finding the effective dose of 188ReO4 (A–C). HepG2 cells viability was measured using LIVE/DEAD® Viability/Cytotoxicity Kit in response to 37, 55, and 73 MBq of 188ReO4 18, 24, and 48 h post-exposure for finding the effective dose of 188ReO4 in treated HepG2 cells (D–F). The IC50 value of 188ReO4 in Huh7 cells was 37 MBq 24 h after exposure, and it was 55 MBq 48 h for HepG2 cells. Data are presented as the mean ± SD, n = 3 (* p < 0.05, ** p < 0.01, and *** p < 0.001, **** p < 0.0001).
Figure 1. 188ReO4 IC50 dose finding on Huh7 and HepG2 cell lines. Huh7 cells viability was measured using LIVE/DEAD® Viability/Cytotoxicity Kit and the mean viability of untreated cells (control group), and the treated groups were compared on various doses of 18, 37, and 55 MBq of 188ReO4 at 18, 24, and 48 h post-exposure for finding the effective dose of 188ReO4 (A–C). HepG2 cells viability was measured using LIVE/DEAD® Viability/Cytotoxicity Kit in response to 37, 55, and 73 MBq of 188ReO4 18, 24, and 48 h post-exposure for finding the effective dose of 188ReO4 in treated HepG2 cells (D–F). The IC50 value of 188ReO4 in Huh7 cells was 37 MBq 24 h after exposure, and it was 55 MBq 48 h for HepG2 cells. Data are presented as the mean ± SD, n = 3 (* p < 0.05, ** p < 0.01, and *** p < 0.001, **** p < 0.0001).
Cells 13 01456 g001
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Asadian, S.; Piryaei, A.; Gheibi, N.; Aziz Kalantari, B.; Reza Davarpanah, M.; Azad, M.; Kapustina, V.; Alikhani, M.; Moghbeli Nejad, S.; Keshavarz Alikhani, H.; et al. Correction: Asadian et al. Rhenium Perrhenate (188ReO4) Induced Apoptosis and Reduced Cancerous Phenotype in Liver Cancer Cells. Cells 2022, 11, 305. Cells 2024, 13, 1456. https://doi.org/10.3390/cells13171456

AMA Style

Asadian S, Piryaei A, Gheibi N, Aziz Kalantari B, Reza Davarpanah M, Azad M, Kapustina V, Alikhani M, Moghbeli Nejad S, Keshavarz Alikhani H, et al. Correction: Asadian et al. Rhenium Perrhenate (188ReO4) Induced Apoptosis and Reduced Cancerous Phenotype in Liver Cancer Cells. Cells 2022, 11, 305. Cells. 2024; 13(17):1456. https://doi.org/10.3390/cells13171456

Chicago/Turabian Style

Asadian, Samieh, Abbas Piryaei, Nematollah Gheibi, Bagher Aziz Kalantari, Mohamad Reza Davarpanah, Mehdi Azad, Valentina Kapustina, Mehdi Alikhani, Sahar Moghbeli Nejad, Hani Keshavarz Alikhani, and et al. 2024. "Correction: Asadian et al. Rhenium Perrhenate (188ReO4) Induced Apoptosis and Reduced Cancerous Phenotype in Liver Cancer Cells. Cells 2022, 11, 305" Cells 13, no. 17: 1456. https://doi.org/10.3390/cells13171456

APA Style

Asadian, S., Piryaei, A., Gheibi, N., Aziz Kalantari, B., Reza Davarpanah, M., Azad, M., Kapustina, V., Alikhani, M., Moghbeli Nejad, S., Keshavarz Alikhani, H., Mohamadi, M., Shpichka, A., Timashev, P., Hassan, M., & Vosough, M. (2024). Correction: Asadian et al. Rhenium Perrhenate (188ReO4) Induced Apoptosis and Reduced Cancerous Phenotype in Liver Cancer Cells. Cells 2022, 11, 305. Cells, 13(17), 1456. https://doi.org/10.3390/cells13171456

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop